Allspring中小型核心主動型ETF ASCE 深 滬
已收盤 04-02 16:00:00 美东时间
28.43
+0.210
+0.74%
華盛通- 最 高28.43
- 今 開27.68
- 成交量 7938股
- 最 低 27.68
- 昨 收 28.22
- 總市值 5552.38万
- 52周最高 32.41
- 市盈率 靜 --
- 換手率 0.41%
- 52周最低 24.0619
- 委 比 0.00%
- 總股本 195.30万
- 歷史最高 32.41
- 量 比 0.47
- 振 幅 2.66%
- 歷史最低 24.0619
- 每 手 1
- 風險率 1.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Our Bond Inc - Enters Amendment No. 2 To Securities Purchase Agreement With Ascent On March 29, 2026 - SEC Filing
BRIEF-Our Bond Inc - Enters Amendment No. 2 To Securities Purchase Agreement With Ascent On March 29, 2026 - SEC Filing March 30 (Reuters) - SEC Filing: OUR BOND INC - ENTERS AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT WITH ASCENT ON MARCH 29, 2026 - SEC FILING OUR BOND, INC. - 8-K OUR BOND INC
03-30 21:26
ADMA Biologics Rebuts Short Seller Claims, Defends Product Demand
ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today responded to a
03-27 19:08
ADMA Biologics drops amid short report from Culper Research
ADMA Biologics (ADMA) fell 15% amid a short report from Culper Research. Culper Research disclosed that it's short shares of ADMA Biologics (ADMA). ADMA (ADMA) didn't immediately respond to Seeking ...
03-25 02:44
Amarin Highlights 2026 ACC/AHA Dyslipidemia Guideline Emphasizing CV Risk Management In Hypertriglyceridemia
Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with
03-18 20:33
Hepion Pharmaceuticals FY 2025 net loss widens 37% to USD 8.28 million as R&D expense falls 96% to USD 0.45 million
Hepion Pharmaceuticals FY 2025 net loss widens 37% to USD 8.28 million as R&D expense falls 96% to USD 0.45 million Hepion reported no revenue for FY 2025 and posted a net loss of USD 8.28 million, narrowing 37% year over year. Loss from operations was USD 4.16 million, narrowing 78%, as research an
03-12 18:07
Amarin Published Data In The European Journal Of Preventive Cardiology Showing That VASCEPA Was Associated With Fewer Hospitalizations In A REDUCE-IT Analysis
Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on
03-02 21:16
ADMA Biologics announces $125M accelerated share repurchase with JPmorgan
ADMA Biologics (ADMA) announced on Monday a capital return initiative target of approximately $200 million during 2026, including the execution of a $125 million accelerated share repurchase (“ASR”) a...
03-02 20:46
BRIEF-Zealand Pharma Announces Positive Phase 1A Topline Results With Kv1.3 Channel Blocker Zp9830
BRIEF-Zealand Pharma Announces Positive Phase 1A Topline Results With Kv1.3 Channel Blocker Zp9830 Feb 18 (Reuters) - Zealand Pharma A/S ZELA.CO : ANNOUNCES POSITIVE PHASE 1A TOPLINE RESULTS WITH KV1.3 CHANNEL BLOCKER ZP9830 ZP9830 WAS WELL TOLERATED IN THIS SINGLE ASCENDING DOSE TRIAL, WITH NO DOSE
02-18 14:36
BRIEF-Ascender Capital Calls For Improved Capital Allocation And Governance At Argo Graphics
BRIEF-Ascender Capital Calls For Improved Capital Allocation And Governance At Argo Graphics Feb 11 (Reuters) - Argo Graphics Inc 7595.T : ASCENDER CAPITAL CALLS FOR IMPROVED CAPITAL ALLOCATION AND GOVERNANCE AT ARGO GRAPHICS (7595) ASCENDER CAPITAL: REQUESTS ARGO FOR ADDITIONAL ¥125 PER‑SHARE SPECI
02-11 23:41
